2-Minute Drill: Biggest Winner From the 2023 ASCO Annual Meeting

EP: 1.2-Minute Drill: The Biggest Surprise From the 2023 ASCO Annual Meeting

EP: 2.2-Minute Drill: Most Practice-Changing Trial From the 2023 ASCO Annual Meeting

EP: 3.2-Minute Drill: FDA Action-Worthy Trials From the 2023 ASCO Annual Meeting

EP: 4.2-Minute Drill: Trials Needing Follow-Up From the 2023 ASCO Annual Meeting

Now Viewing

EP: 5.2-Minute Drill: Biggest Winner From the 2023 ASCO Annual Meeting

EP: 6.2-Minute Drill: Shameless Plus From the 2023 ASCO Annual Meeting

EP: 7.2-Minute Drill: Closing Thoughts on the 2023 ASCO Annual Meeting

EP: 8.ASCO 2023: Experts Recount the Biggest Surprises and Most Relevant Research

Following the 2023 ASCO Annual Meeting, Ruemu E. Birhiray, MD, Hematology Oncology of Indiana; Sameer A. Parikh, MBBS, Mayo Clinic; Javier Pinilla, MD, PhD, Moffitt Cancer Center; and Nakhle Saba, MD, Tulane University School of Medicine, discuss the biggest winner that came out of the meeting.

The participants had 30 seconds each to give their response.

Kahl: Okay, so studies aside, this next topic can be on anything that's out of ASCO. So it can be trials, data, a certain drug, a presenter, the meeting itself, you name it. 30 seconds each: Who or what was the biggest winner out of ASCO this year? Dr. Birhiray, let's start with you.

Birhiray: I will say again, my biggest winner was Alex Herrera, [MD]. He presented data at a plenary session. So when you walk down the hallway at ASCO, there was a big battle that talked about equity and trying to make sure everyone was taken care of. And that did happen, and having been presented was so powerful that I went to the green room and I gave him a hug and I kissed him on the check.

Kahl: Alright, 30 points. Dr. Pinilla?

Pinilla: Definitely that was a really, really big thing. I think I’m going to go with themes. I was impressed by the large amount of BiTES and CAR T technologies that are really erupting in multiple myeloma specifically, [a disease] I don't [treat]. But definitely, I was really shocked by the amount of activity in this area.

Kahl: Absolutely, 40 points. Dr. Parikh?

Parikh: So, I think this was really a presentation that caught my attention was by Monica Bertagnolli, MD, she was at [Dana-Farber Cancer Institue], and now likely going to be at the NIH and the main person that I think when she was talking and presenting and she was showing a Kaplan Meier curve, she was talking about how every step down in the Kaplan Meier curve really represents an event which to us, as investigators, is a step down. But, in fact, affects the quality and the quantity of each person. And there is a story behind each of these patients that I think is important for us to recognize as we talk about overall survival, progression-free survival, and I think she just brought that humane sort of aspect to the whole discussion, which I found was very powerful.

Kahl: Absolutely. You did go over a little bit there. So I'm going to go 20 points on that one. Sorry to do that to you. Alright, Dr. Saba?

Saba: I'm going to stay a little classic and choose a drug, golidocitinib, which is a JAK1 inhibitor In peripheral T-cell lymphoma. This is a disease that most lymphoma specialists don't like. You need to really be focused on that to treat it. But finally, a drug that is not really heavily investigated in in B-cell lymphoma, and now it's showing really promising efficacy in relapsed/refractory peripheral T-cell lymphoma disease that has a lot of unmet needs.

Kahl: Alrighty, 40 points there.

Transcription edited for clarity.